A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3517
Abstract: Purpose: DNA mismatch repair (MMR) deficiency is a hallmark of Lynch syndrome, the most common inherited cancer syndrome. MMR-deficient cancer cells accumulate numerous insertion/deletion mutations at microsatellites. Mutations of coding microsatellites (cMS) lead to the… read more here.
Keywords: mmr deficient; trial; cancer; phase iia ... See more keywords
Abstract A107: Development of polymerase theta inhibitors for precision medicine in BRCA-deficient cancers
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-a107
Abstract: DNA polymerase theta (Polq) is important for the proliferation of BRCA-deficient cancer cells, but is dispensable for normal cell growth. Thus, Polq is widely considered to be an important new drug target for BRCA-deficient cancers,… read more here.
Keywords: medicine; brca deficient; polymerase theta; deficient cancers ... See more keywords
Abstract 6190: Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6190
Abstract: Cancers deficient in homologous recombination (HR) repair secondary to mutations in genes such as BRCA1 or BRCA2, are dependent on alternative DNA damage response (DDR) pathways to maintain genomic integrity, rendering them susceptible to synthetic… read more here.
Keywords: inhibition; pol inhibition; deficient; deficient cancers ... See more keywords
In Silico Investigation of the Molecular Mechanism of PARP1 Inhibition for the Treatment of BRCA-Deficient Cancers
Sign Up to like & getrecommendations! Published in 2023 at "Molecules"
DOI: 10.3390/molecules28041829
Abstract: The protein PARP1, which plays a crucial role in DNA repair processes, is an attractive target for cancer therapy, especially for BRCA-deficient cancers. To overcome the acquired drug resistance of PARP1, PARP1 G-quadruplex (G4) identified… read more here.
Keywords: parp1 parp1; brca deficient; deficient cancers; parp1 ... See more keywords